Home / Inspections / 1219018

FDA Inspection 1219018 — Mylan Pharmaceuticals Inc

Mylan Pharmaceuticals Inc — FEI 1110315

The FDA completed an inspection of Mylan Pharmaceuticals Inc on August 18, 2023 in Morgantown, WV. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
August 18, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Morgantown, WV (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Facility

Other inspections at this facility

  • 1311680 (NAI Tue Apr 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1170444 (VAI Thu May 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1099590 (VAI Thu Aug 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1076082 (NAI Fri Nov 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1072148 (NAI Wed Nov 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time))

Recent compliance actions

FDA data resources